Skip to main content

Indian Pharma Network

Neonatal-onset multisystem inflammatory disease (NOMID) is the most severe form of cryopyrin-associated periodic syndromes (CAPS). Kineret (anakinra) is approved in the United States to treat NOMID. This article explains how the medicine works in NOMID, how doctors set the dose, and what is checked during treatment. If you first want to understand the condition itself, read our guide on what NOMID is and how it shows up in babies.

How does Kineret work in NOMID?

In NOMID, a change in the NLRP3 gene makes the body release too much interleukin-1 (IL-1), a signal that drives inflammation. Kineret is a copy of the body’s own IL-1 receptor antagonist. It attaches to the IL-1 receptor and blocks IL-1 from acting, which reduces fever, rash, joint swelling and inflammation in the brain lining. It treats the inflammation; it does not change the gene.

Is Kineret approved for NOMID?

Yes. The US prescribing information lists NOMID as an approved use, along with deficiency of interleukin-1 receptor antagonist (DIRA) and rheumatoid arthritis in adults. In the European Union, Kineret is authorised for all forms of CAPS, including NOMID (also called CINCA), in children from 8 months of age who weigh at least 10 kg. NOMID is one part of the wider CAPS family of autoinflammatory diseases.

How is the dose worked out?

In NOMID the dose is based on body weight, not a fixed amount. According to the US Kineret label on DailyMed:

  • The usual starting dose is 1–2 mg per kg of body weight once a day, injected under the skin.
  • The doctor adjusts the dose in small steps of 0.5–1 mg/kg depending on how well inflammation is controlled.
  • The maximum dose studied is 8 mg/kg per day. Once-daily dosing is usual, but the daily dose may be split into two injections.
  • In severe kidney impairment, the doctor may consider dosing every other day.

Kineret comes as a 100 mg/0.67 mL prefilled syringe. The syringe is graduated, so smaller doses for children can be measured. Only the treating specialist should decide or change the dose.

What do doctors monitor during treatment?

  • Response – fever, rash, joint symptoms and blood markers such as CRP and serum amyloid A.
  • Infections – Kineret lowers part of the immune defence, so serious infections need prompt attention, and treatment may be paused.
  • Neutrophil count – the label advises checking white cells (neutrophils) before starting and regularly during treatment.
  • Vaccines – live vaccines should not be given during treatment, so vaccination plans are checked in advance.
  • Long-term organ checks – hearing, eyes and kidneys, because NOMID can harm them over time.

What side effects were seen in NOMID studies?

In the US label, the most common side effects in NOMID patients during the first 6 months were injection-site reactions, headache, vomiting, joint pain, fever and nasopharyngitis (a cold-like infection). Allergic reactions and serious infections are less common but important. Our article on safety precautions with Kineret covers these warnings in more detail.

Are there other treatment options?

Canakinumab (Ilaris) and rilonacept (Arcalyst) also block IL-1. In the US they are approved for the milder CAPS forms (FCAS and Muckle-Wells syndrome), not for NOMID. Of the three, anakinra is the one whose US label includes NOMID.

Frequently asked questions

How long does a child with NOMID need Kineret?

NOMID is a lifelong condition, and symptoms usually return if treatment stops. The specialist reviews the treatment plan at each visit.

Can parents give the injection at home?

Kineret is designed for subcutaneous injection, and families are usually trained by the care team before giving it at home.

How can patients in India get Kineret?

Patients with a prescription can contact Indian Pharma Network for sourcing and import support. Product details and how to enquire are on our anakinra (Kineret) availability page.

References

  • Kineret (anakinra) US prescribing information, Sobi (revised 10/2025) – DailyMed.
  • European Medicines Agency – Kineret EPAR, product information.
  • Ilaris (canakinumab) and Arcalyst (rilonacept) US prescribing information – DailyMed.

Last updated: 20 November 2026. This article is for information only and does not replace advice from your doctor. Kineret is a prescription medicine.

Nitin Goswami

Nitin Goswami joined us as an Editor in 2020. He covers all the updates in the field of Pharmaceutical, Business Healthcare, Health News, Medical News, and Pharma News.

Leave a Reply